

In re Application of: Kiesewetter et al.  
Application No. 09/648,651  
Filed: January 18, 2001  
For: METAL-CONTAINING RIBONUCLEOTIDE POLYPEPTIDES

COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

Transmitted herewith is a response to an office action in the subject application.

☐ Applicants claim small entity status of this application under 37 CFR 1.27.

☒ Petition for Extension of Time

☐ Applicants petition for a one-month extension of time under 37 CFR 1.136, the fee for which is \$110.00 (enclosed).

☒ Applicants believe that no petition for an extension of time is necessary. However, to the extent that such petition is deemed necessary, Applicants hereby petition for a sufficient extension of time to render the present submission timely. Please charge Deposit Account No. 12-1216 for the appropriate petition fee.

☒ No additional claim fee is required.

☒ Other: 1) Amendments to Claims Made in Response to Office Action Dated September 19, 2002; 2) Pending Claims after Amendments Made in Response to Office Action Dated September 19, 2002; 3) Return Postcard

The claim fee has been calculated as shown below:

					SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	EXTRA CLAIMS PRESENT	RATE	ADDIT. CLAIM FEE	RATE	ADDIT. CLAIM FEE
TOTAL	3	MINUS	20	=0	x 9=	\$	x 18=	\$0.00
INDEPENDENT	1	MINUS	3	=0	x 42=	\$	x 84=	\$0.00
<input type="checkbox"/>	FIRST PRESENTATION OF MULTIPLE CLAIM				+ 140=	\$	+ 280=	\$
					TOTAL	\$	TOTAL	\$0.00

☐ Please charge my Deposit Account No. 12-1216 in the amount of \$ . A duplicate copy of this sheet is attached.

☐ A check in the amount of \$ is attached.

☒ The Commissioner is hereby authorized to charge any deficiencies in the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-1216. A duplicate copy of this sheet is attached.

☒ Any filing fees under 37 CFR 1.16 for the presentation of extra claims.

☒ Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

LEYDIG, VOIT & MAYER, LTD.

By

Salim A. Hasan, Reg. No. 38,175

Leydig, Voit & Mayer, Ltd.  
Two Prudential Plaza, Suite 4900  
180 North Stetson  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

In re Appln. of Kiesewetter et al.  
Application No. 09/646,651

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 10-21-2002

Mark C. Swartz



**PATENT**  
Attorney Docket No. 206579

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Kiesewetter et al.

Group Art Unit: 1635

Application No. 09/646,651

Examiner: J. Schultz

Filed: January 16, 2001

For: METAL-CONTAINING RIBONUCLEOTIDE  
POLYPEPTIDES

**RECEIVED**

OCT 31 2002

TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated September 19, 2002, please enter the following amendments and consider the following remarks.

**AMENDMENTS**

*Please replace the indicated claims as follows:*

9. (Amended) ~~A process for producing a metal-containing ribonucleotide protein (RPN) according to claim 8, characterized in that leucocytes or inflammation tissue is homogenized or leucocytes are cultivated and the resulting RNP is recovered from the homogenates or from the supernatant of the culture solution by standard methods.~~

10. (Amended) ~~A use of the metal-containing ribonucleotide protein (RPN) according to claim 8 and/or molecular-biological equivalent structures and/or fragments and/or derivatives for producing a medicament for specifically influencing angiogenesis.~~